| Name | Title | Contact Details |
|---|
One of every nine Americans is a member of an Anthem, Inc. affiliated health plan. For us, that`s a tremendous privilege and responsibility. Our focus every day is on improving the lives of the people we serve and the health of our communities. The foundation of our work can be summarized by: Delivering consistent service and becoming faster and simpler with every action we take. Creating the best health care value for our customers Investing where returns are the greatest to make the best use of our current assets. Being a market leader in each of our chosen businesses. Continuing to advocate for responsible health care reform.
Retirement Concepts is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Darena Solutions delivers an ecosystem of FHIR® enabled interoperability, regulatory compliance, and analytics solutions to healthcare providers and payers. By creating channels for data sharing between providers, payers, and patients, our solutions enable healthcare organizations to achieve compliance and derive insights to make prospective decisions resulting in increased workflow efficiencies and better patient outcomes.
Association of California Healthcare Districts is a Rancho Cordova, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.